News | March 23, 2012

VAP Cholesterol Test Helps Researchers Study Dyslipidemia, Assess Anti-Flushing Agent

March 23, 2012 — Researchers using the VAP (vertical auto profile) Cholesterol Test to isolate lipid subfractions and assess a new anti-flushing agent have reported significant baseline reductions in the cholesterol content of lipoproteins across the entire very low density lipoprotein (VLDL) to low density lipoprotein (LDL) density range in dyslipidemic patients.

In the study “Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia,” published in the Journal of Clinical Lipidology, researchers conducted a predefined exploratory analysis of a large, double-blind, randomized active-controlled study that previously evaluated the effectiveness of the anti-flushing drug Laropiprant (LRPT) when combined with extended release niacin (ERN) and simvastatin (SIM). Despite its proven cardioprotective benefits, niacin has not been well tolerated due to the unpleasant side effect of flushing. LRPT proved to be well tolerated in the large randomized study, and ERN/LRPT plus simvastatin significantly improved patients’ lipid profile compared with ERN/LRPT and simvastatin alone.

Ballantyne et al. examined the individual and combined effects of ERN/LRPT and SIM on lipoprotein subfractions as isolated by the VAP Cholesterol Test methodology, which separates lipoprotein fractions based on their inherent molecular properties (size and density). Researchers evaluated the effects of: ERN/LRPT plus SIM; ERN/LRPT; and SIM alone on percent change from baseline to week 12 in cholesterol associated lipoproteins. Researchers reported:

  • Significant baseline reductions in LDL and dense LDL subclasses;
  • Significant baseline increases in high denisty lipoprotein (HDL) with larger increases in HDL2; and
  • Significant baselines reductions in triglyceride rich lipoproteins VLDL1+2, VLDL3 and IDL.

Lead author Christie Ballantyne, M.D., said previous studies that examined the effects of niacin on lipid subclasses have shown that niacin favorably shifts the ratio of small to large HDL and LDL particles toward a more cardioprotective distribution. However, he said this marks the first use of the VAP Test for such an analysis.

“To our knowledge, we are the first to use the VAP Test to compare the individual and combined effects of niacin and statin on lipoprotein subfractions,” said Ballantyne. “By isolating a broad array of lipoprotein subfractions, we were able to quantify the cholesterol within each lipoprotein fraction, enabling a more precise picture of dyslipidemia and the effects of medications on these lipoprotein parameters.”

Lipoproteins isolated by the VAP Test for the study included: VLDL, VLDL subclasses (VLDL1+2, VLDL3); IDL; LDL-R (Real LDL, excluding the contribution of IDL and Lp(a) typically included in standard LDL measurements); LDL subclasses (LDL1, LDL2, LDL3, LDL4); Lp(a); HDL and HDL subclasses (HDL2, HDL3).

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init